USPTO serial 76191699
TARGESOME
Reviewed by CopyMark Law Group
Status 606
- Filing date
- Status date
- Registration date
- —
- Examiner
- FRENCH, CURTIS W
- Law office
- FILE REPOSITORY (FRANCONIA)
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with TARGESOME?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
THOMAS D. BRATSCHUN
THOMAS D BRATSCHUN SWANSON & BRATSCHUN, L.L.C.1745 SHEA CTR DR STE 330HIGHLANDS RANCH, CO 80129UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical preparations that aid in the transport and delivery of diagnostic, therapeutic and imaging agents for the treatment of tumor metastasis, solid tumor growth, osteoporosis, Paget's disease, humoral hyperglycemia of malignancy, angiogenesis, including tumor angiogenesis, retinopathy, macular degeneration, arthritis, including rheumatoid arthritis, periodontal disease, psoriasis and smooth muscle cell migration, diseases associated with neovascular growth, namely, solid tumors, blood borne tumors, leukemia, tumor metastastasis, benign tumors, acoustic neuromas, neurofibromas, trachomas, and pyogenic granulomas, rheumatoid arthritis, psoriasis, chronic inflammation, ocular angiogenic diseases, diabetic retinopathy, retinopathy of prematurity, macular degeneration, corneal graft rejection, neovascular glaucoma, retrolental fibroplasia, rubeosis, arteriovenous malformations, ischemic limb angiogenesis, Osler-Webber Syndrome, myocardial angiogenesis, plaque neovascularization, telangiectasia, hemophiliac joints, angiofibroma, and wound granulation, diseases of excessive or abnormal stimulation of endothelial cells, namely, intestinal adhesions, atherosclerosis, restenosis, scleroderma, and hypertrophic scars | ACTIVE | — |
| 010 | Medical devices, namely, polymerized nanoparticles for the transport and delivery of diagnostic, therapeutic and imaging agents | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jul 9, 2004 | ABN6 | ABANDONMENT - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Dec 4, 2003 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Nov 24, 2003 | EXT1 | SOU EXTENSION 1 FILED | — |
| Nov 24, 2003 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| May 27, 2003 | NOAM | NOA MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Mar 4, 2003 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Feb 12, 2003 | NPUB | NOTICE OF PUBLICATION | — |
| Dec 23, 2002 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Dec 20, 2002 | CNEA | EXAMINERS AMENDMENT MAILED | — |
| Dec 19, 2002 | ZZZX | PREVIOUS ALLOWANCE COUNT WITHDRAWN | — |
| Dec 18, 2002 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Dec 11, 2002 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Dec 6, 2002 | CNEA | EXAMINERS AMENDMENT MAILED | — |
| Dec 5, 2002 | DOCK | ASSIGNED TO EXAMINER | — |
| Oct 8, 2002 | ZZZX | PREVIOUS ALLOWANCE COUNT WITHDRAWN | — |
| Oct 8, 2002 | DOCK | ASSIGNED TO EXAMINER | — |
| Oct 7, 2002 | DOCK | ASSIGNED TO EXAMINER | — |
| Sep 27, 2002 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Sep 9, 2002 | DOCK | ASSIGNED TO EXAMINER | — |
| Sep 6, 2002 | REIN | REINSTATED | — |
| Jun 10, 2002 | PETR | PETITION TO REVIVE-RECEIVED | — |
| Jun 6, 2002 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| May 27, 2002 | ABN2 | ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| May 24, 2001 | CNRT | NON-FINAL ACTION MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 2, 2001 | DOCK | ASSIGNED TO EXAMINER | — |
| Apr 27, 2001 | DOCK | ASSIGNED TO EXAMINER | — |